Some interesting early drugs in development were presented in a packed session this morning, across a wide variety of targets and tumour types. The four that stood out from the pack to me were:

1) MEDI4736 (anti-PD-L1)

2) GDC-0980 (dual PI3K/mTOR)

3) BKM120 (buparlisib) + GSK112 (trametinib) (PI3K + MEK)

4) alectinib (ALK)

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase personal access to all Premium Content. Current subscription rate is $399 for 3 months access and $1200 for 12 months access. Please contact us if you would like to purchase annual access. Subscriptions do not auto renew. Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals.